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ABSTRACT 
 
 
Background 
Recent attention to the management of atrial fibrillation 
(AF) and stroke prevention has emphasised the need to 
support the use of existing pharmacotherapy through 
available services and resources, in preference to using the 
new, more expensive, novel oral anticoagulants. In this 
regard, general practitioners (GPs) are at the core of care. 
 
Aims 
To survey Australian GPs regarding their approach to 
managing AF, particularly in relation to stroke prevention 
therapy, and to identify the range of services to support 
patient care. 
 
Methods  
A structured questionnaire, comprising quantitative and 
qualitative responses, was administered to participating GPs 
within four geographical regions of NSW (metropolitan, 
regional, rural areas). 
Results  
Fifty GPs (mean age 53.74±9.94 years) participated. Most 
(98 per cent) GPs regarded themselves as primarily 
responsible for the management of AF, only referring 
patients to specialists when needed. However, only 10 per 
cent of GPs specialised in “heart/vascular health”. Most (76 
per cent) GPs offered point-of-care international normalised 
ratio (INR) testing, with 90 per cent also offering patient 
support via practice nurses and home visits. Overall, key 
determinants influencing GPs’ initiation of antithrombotic 
therapy were: “stroke risk”/”CHADS2 score”, followed by 
“patients’ adherence/compliance”. GPs focused more on 
medication safety considerations and the day-to-day 
management of therapy than on the risk of bleeding.  
 
Conclusion 
Australian GPs are actively engaged in managing AF, and 
appear to be well resourced. Importantly, there is a greater 
focus on the benefits of therapy during decision-making, 
rather than on the risks. However, medication safety 
considerations affecting routine management of therapy 
remain key concerns, with patients’ adherence to therapy a 
major determinant in decision-making. 
 
Key Words 
Atrial fibrillation, stroke prevention, general practitioners, 
pharmacotherapy, antiarrhythmic, antithrombotic 
 
What this study adds:  
1. What is known about this subject?  
AF management is becoming increasingly complex, 
particularly around therapeutic decision-making, yet there 
is limited information about how well supported Australian 
GPs are in terms of resources. 
 
2.  What new information is offered in this study? 
GPs have access to various services and resources to 
support their management of AF patients. Key determinants 
in GPs’ decision-making relate to perceived benefits of 
 358 
 
[AMJ 2015;8(11):357–367] 
 
therapy, and day-to-day management issues, more so than 
the risks. 
 
3. What are the implications for research, policy, or 
practice?  
Targeted interventions are needed to better support GPs in 
managing patients with cognitive or functional impairments, 
and those patients who are non-adherent to therapy.  
 
Background 
Atrial fibrillation (AF) is a major contributor to the burden of 
stroke in Australia, on the background of an ageing 
population, and the increasing prevalence of heart disease.
1
 
Recent Australian data highlight that strokes attributed to 
AF are often more severe in presentation, with a higher 
mortality rate, than other types of stroke,
2
 consistent with 
international findings.
3
 For this reason, the management of 
AF has become a clinical priority, with attention focused on 
the use of antithrombotic and antiarrhythmic therapies. 
Previous studies have shown that use of these therapies has 
been suboptimal,
4–7
 particularly in the at-risk elderly 
population, with clinicians citing a range of barriers to 
optimal management, including: difficulty in applying 
guidelines to clinical practice; concerns about the risk versus 
benefit of therapy in elderly patients; and lack of adequate 
support to effectively manage patients using complex 
anticoagulant or antiarrhythmic therapies.
8,9
 
 
In Australia, as far back as 1997, the National Health and 
Medical Research Council guidelines
10
 have stated: “General 
Practitioners … are the key to better stroke prevention. 
What is needed is proactive opportunistic screening and risk 
management, and prompt action for two groups of patients: 
those with stroke/TIA symptoms and those with atrial 
fibrillation”.
11
 This has set the scene, over the past decade, 
for the implementation of targeted interventions to assist 
general practitioners (GPs) in managing patients with AF, 
including the use of risk assessment tools, practical 
guidelines, point-of-care testing for warfarin therapeutic 
monitoring, and patient education resources.  
 
More recently, the advent of new treatment options, i.e., 
the novel oral anticoagulants (NOACs), has re-focused 
attention on the management of AF.
12
 Given the significant 
costs of the NOACs and their potential impact on health-
system expenditure, a government report’s
13
 
recommendations emphasise the need to optimise 
management of AF through existing pharmacotherapy (e.g., 
warfarin), existing services, and resources (e.g., point-of-
care testing). In considering the report’s recommendations, 
it is important to first understand the contemporary 
approach to the management of persons with AF in general 
practice. Therefore, the aim of this study was to canvas 
Australian GPs regarding their approach to managing AF, 
particularly in relation to stroke prevention therapy, and to 
identify the range of services they used to support their care 
of patients. 
 
Method 
Study design 
A structured questionnaire was administered to 
participating GPs over a three-month period in 2012. The 
questionnaire was purpose-designed to determine GPs’ 
approaches to the management of patients with AF; access 
and use of services to support patient care; and factors 
influencing their management of AF. Approval was granted 
from the relevant institutional Human Research Ethics 
Committees (Protocol 12453; HREC 2011-348A). 
 
Sample frame 
The participating GPs were from four Divisions of General 
Practice (DGP) or Medical Locals
14
 (more recently known as 
Primary Health Care Networks) in the state of New South 
Wales (NSW), Australia, who were originally recruited to 
participate in an intervention trial addressing stroke 
prevention in AF.
15
 The geographical divisions (i.e., City 
Metropolitan (CM), Coastal Region (CR), Regional Urban 
(RU), Regional Rural (RR)) were purposively selected to 
accommodate a cross-section of GPs caring for patients 
from diverse backgrounds (i.e., socio-economic, health 
status, access to health services) within both rural and 
urban settings in Australia. 
 
Recruitment methods 
GPs were invited to participate in the original intervention 
trial through advertisements for expressions of interest, 
which were distributed by the relevant DGP. GPs were then 
recruited into the trial, subject to meeting eligibility 
criteria,
15
 and invited to complete the questionnaire. All 
participating GPs were informed that the trial was exploring 
AF management and the use of therapy for stroke 
prevention. Eligible GPs were those who: were practicing in 
one general practice surgery and not across multiple sites or 
surgeries; practiced in the specified divisions of GP; and 
provided informed written consent to participate in the 
study. 
 
Sample size calculation  
The sample size was estimated based on previous data as 
well as the requirements of the intervention trial to which 
the GPs were originally recruited.
15
 For this specific 
descriptive sub-study, the main trial sample provided 
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sufficient participants to meet the stated objectives; i.e., 
using a point estimate of 25 per cent (i.e., estimated 
proportion of GPs using specific services to support their 
management of AF patients) with 95 per cent confidence 
and 10 per cent degree of precision, a target of 50 GPs 
recruited over a three-month period was required (in line 
with the main trial).  
 
Data collection and analysis 
The purpose-designed questionnaire was distributed in 
paper format to the GPs by the study’s project officers (in 
person), who also verified specific inputs (e.g., clarification 
regarding the nature of services available in the practice).  
 
Computerised analysis of quantitative data was performed 
using IBM SPSS Statistics 20 (IBM Corp; Armonk: NY). The 
Chi-square test, Mann-Whitney U test, and Kruskal-Wallis 
test were used to examine differences in independent 
proportions (parametric and non-parametric distributions, 
respectively). ANOVA was used to test for mean differences 
in continuous variables. A significance level of five per cent 
(p<0.05) was set for all analyses. Open-ended responses to 
specific questions were thematically analysed, using manual 
inductive coding by the project officer and verified by the 
lead researcher. 
 
Results 
Characteristics of the GPs 
On average, the 50 participating GPs were 53.74±9.94 years 
old with 22.88±10.14 years of experience in practice; 35 
(70.0 per cent) were male (Table 1). GPs in the City 
Metropolitan region were older in age than those in other 
regions (p=0.01). There were no significant differences 
across the four practice regions in terms of the GPs’ gender 
distribution (p=0.63) or years of experience in practice 
(p=0.21). The characteristics of the GPs were typical of the 
wider Australian GP setting in terms of age and years of 
experience, and comparable to that reported in the Better 
the Evaluation and Care of Health (BEACH) program (a 
continuous cross-sectional national study).
16
 However, there 
was a higher proportion of male GPs in the present study 
(versus 57 per cent in the BEACH program). 
 
Characteristics of the practice setting 
Overall, the most common type of setting that these GPs 
practiced in was a “medium-sized medical centre” (i.e., 4–5 
GPs; 30.0 per cent of all GPs) (Table 1). 
 
General practice areas of specialisation 
While all of the GPs were obviously focused on 
general/family practice, one-fifth (22 per cent) additionally 
specialised in Women’s Health, followed by Aged Care (14 
per cent). Only 10 per cent reported specialising in 
Heart/Vascular Health (under which the management of AF 
would fall).  
 
GPs practicing in the Coastal Region and Regional Rural 
areas reported additional specialties of practice, compared 
with those in the Regional Urban and City Metropolitan 
areas; only one GP in the City Metropolitan area reported a 
specialisation (Aged Care). Among the group of “Other” 
reported specialty areas (n=5 GPs) were: “anaesthetics” 
(n=1 GP, Rural Region), “mental health” (n=1 GP, Regional 
Urban), “skin cancer” (one GP each in the Regional Rural 
and Coastal Region), and “travel and diving diseases” (n=1 
GP, Coastal Region).  
 
Diagnostic services provided in general practice 
In regard to the diagnostic and monitoring services provided 
by these GPs, the most commonly reported were: urine 
testing (e.g., screening tests, test strips), followed by 
respiratory tests (e.g., peak flow meters) and cardiovascular 
(e.g., ECG–electrocardiograms, halter monitors) tests. One 
GP offered “24-hour blood pressure monitoring” (Coastal 
Region). Approximately three-quarters of GPs provided on-
site pathology collection services. Point-of-care testing (e.g., 
anticoagulation tests) was offered by most (76 per cent) GPs 
(Table 1). In terms of “other” diagnostic services offered by 
these GPs, one GP offered “laser” (Regional Urban), and one 
GP offered “dopplers” (Coastal Region).  
 
Patient support services provided in general practice 
In regard to patient support services, 90 per cent of GPs 
provided home visits as well as access to an on-site practice 
nurse. Most GPs (70 per cent) also provided access to 
medication management reviews. Other services reported 
by GPs included an “off-site after-hours clinic” (one GP) and 
“pharmacy next door” (one GP).  
 
Overall, there were no major differences across the practice 
regions in terms of practice type, specialisation, diagnostic 
services, and patients support services (p>0.05).  
 
Management of patients with atrial fibrillation 
Overall, most GPs estimated that one-quarter of their 
patient base (in their current practice setting) was elderly 
(i.e., ≥65 years of age); 32 per cent of GPs estimated the 
proportion to be 10–25 per cent, while 34 per cent 
estimated it as 25–50 per cent. A higher proportion of GPs 
practicing in the Coastal Region reported that 50–75 per 
cent of their patient base was elderly (Table 1). The GPs also 
estimated that, overall, one-quarter of their elderly patient 
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base (i.e., patients ≥65 years of age) had a diagnosis of AF 
(persistent, permanent, chronic AF); 42 per cent of GPs 
estimated the proportion to be 10–25 per cent, and 38 per 
cent estimated this proportion to be 25–50 per cent.  
 
Responsibility for the management of AF 
Most GPs (n=49, 98 per cent) reported that they maintained 
primary responsibility for the management of their patient’s 
AF therapy; only one GP from the total sample reported 
that a cardiologist was primarily responsible for their 
patients’ AF management, while one GP specifically stated 
that they maintained responsibility for the patients 
management in “liaison with the cardiologist” (Table 2).  
 
Specialist management of AF 
In relation to specialist management of AF, half of the GPs 
(n=27, 54 per cent) reported that they referred their 
patients to specialist management of antiarrhythmic 
therapy only “when needed”, while 32 per cent referred to 
specialist management “for initial assessment only”; only 
one GP referred to specialist management “for initial and 
regular follow-up (complete management)” of their 
antiarrhythmic therapy (Table 2). For antithrombotic 
therapy, a higher proportion of GPs reported that they 
referred patients to specialist management only “when 
needed” (n=36, 68 per cent); 20 per cent of GPs indicated 
referring patients “for initial assessment only”. Only one GP 
referred to specialist management “for initial and regular 
follow-up (complete management)” of their antithrombotic 
therapy. 
 
On-site services for the management of AF 
For more than half of the GPs (n=29 GPs, 59.2 per cent) the 
monitoring and management of their warfarinised patients 
comprised testing in a local pathology clinic combined with 
subsequent GP follow-up and review of results. More than 
67.3 per cent of GPs (n=33) provided on-site monitoring and 
review services (at the general practice) for warfarinised 
patients. GPs also used on-site practice nurses (n=45 GPs, 
90 per cent) and home visits (n=45 GPs, 90 per cent) as part 
of the support offered to anticoagulated patients. 
 
Determinants of the use of antithrombotic therapy 
The GPs were asked to nominate their key determinants (up 
to a maximum of five) in decision-making for the initiation 
of antithrombotic therapy in an individual patient, ranking 
the factors in order of importance (i.e., first, second, third, 
etc., determinants).  
 
As a first determinant, most commonly stated were the 
“CHADS2 score”, specifically (n=15 GPs, 29.4 per cent), 
followed by a generic statement about “stroke risk” (n= 9 
GPs, 17.6 per cent), then a “confirmed diagnosis of AF” (n=7 
GPs, 13.7 per cent) (Table 3).  
 
As a second determinant, most commonly stated were 
“stroke risk” (n=7 GPs, 13 per cent), “cognitive 
status/mental status of patient” (n=6 GPs, 11.1 per cent), 
“patient’s comorbidities” (n=5 GPs, 9.3 per cent), and 
“safety of therapy” (n=5 GPs, 9.3 per cent) (Table 3).  
 
As a third determinant, most commonly stated were 
“cognitive status/mental status of patient” (n=11 GPs, 21.2 
per cent), followed by “patient’s adherence/compliance” 
(n=9 GPs, 17.3 per cent), and “confirmed diagnosis of AF” 
(n= 5 GPs, 9.6 per cent) (Table 3). 
 
Overall, across all the factors stated by the GPs in any 
ranking, the most frequently stated determinants were 
“stroke risk” (n=19, 9.4 per cent) and “CHADS2 score” (n=17, 
8.4 per cent), followed by “patient’s 
adherence/compliance” (n=17, 8.4 per cent), “confirmed AF 
diagnosis” (n=15, 7.4 per cent), and “patient age” (n=15, 7.4 
per cent). “Stroke risk” and “CHADS2 score” were cited as 
determinants by 38 per cent (19/50) and 34 per cent 
(17/50) of GPs, respectively. There were no significant 
differences in the citation and ranking of determinants 
across the four practice regions. 
 
Qualitative analysis subsequently categorised the cited 
determinants into three main themes, aligning with the 
categorisation of decision-making factors, as reported in 
previous studies:
17
  
 
 Perceived benefit of therapy 
 Risks associated with therapy 
 Medication safety considerations 
 
The perceived benefit of therapy was ranked as a first 
priority in the decision to initiate antithrombotic therapy, 
with the patient’s “stroke risk” (as assessed by the CHADS2 
score) cited as the main factor. Additionally, GPs cited the 
need to “confirm the diagnosis of AF” (potentially indicating 
consideration as to whether the AF is “permanent” or 
“chronic”) and the overall “treatment” strategy (potentially 
referring to any advice received from specialists) prior to 
initiating therapy. Furthermore, GPs mentioned “other 
cardiovascular problems” and “comorbidities” as influences 
on decision-making, in recognition of the contribution of 
these to the overall stroke risk and/or additional indications 
for antithrombotic therapy. Interestingly, “life quality” was 
also mentioned here, reflecting consideration of any 
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benefits relative to the risks and management issues for the 
target elderly population. 
 
Surprisingly, factors associated with the perceived risks of 
therapy did not rank very highly as key determinants of 
therapy; the risk of bleeding was not explicitly stated by any 
of the GPs, although “safety” was generically mentioned. In 
broad terms, GPs highlighted the need to consider 
“contraindications” to therapy and the patient’s “suitability 
for anticoagulation”, although no specific assessment of the 
risk of bleeding was mentioned. 
 
Most of the determinants cited by GPs fell within the 
medication safety theme, describing patient and system 
factors affecting the day-to-day use and management of 
therapy. Patient-related factors commonly cited were 
“age”, “adherence/compliance”, “cognitive/mental state”, 
“falls risk”, and “medication/drug interactions”. In regard to 
system-related factors, “monitoring and support” was the 
key issue cited. Overall, the GPs were more likely to focus 
on the medication safety issues that underpinned the 
success of therapy, than an explicit assessment of the risk of 
bleeding. 
 
Discussion 
Overall, the findings from this study are encouraging, and 
show an evolution in the approach to managing patients 
with AF, specifically in managing antithrombotic therapy, in 
the Australian general practice setting. This temporal 
improvement in the approach to the management of AF 
patients suggests that GPs are confident and well-resourced 
in assuming the primary responsibility for management of 
these patients, whereas historically GPs referred patients 
for specialist management usually by cardiologists or 
neurologists.
8,18
 This may reflect their increased ability to 
apply treatment guidelines, following the implementation of 
key interventions over the past decade to address 
previously reported barriers to the prescription of 
anticoagulant therapy, i.e., the inability to apply evidence-
based guidelines to practice, use of risk assessment tools to 
assist with decision-making (e.g., CHADS2 criteria),
19
 and 
concerns about the use of anticoagulants in “elderly” 
patients.
 8,18
 
  
Previous studies have reported an age bias in the 
prescribing of antithrombotic therapy, with anticoagulants 
(specifically warfarin) reportedly underused in older 
persons.
5,20–22
 However, in the present study, GPs seldom 
cited “old age” per se as a specific determinant in decision-
making. Instead, GPs focused on a diverse range of factors 
that impact on the routine day-to-day management of 
therapy, the so-called medication safety considerations. 
Although many of these factors are age-related, e.g., 
cognitive impairment, functional impairment, and the risk of 
falls,
23
 they can be present in all patients and can be 
independently assessed and potentially addressed through 
appropriate patient support services. The de-emphasis on 
“old age” highlights a more sensitive understanding by GPs 
of the factors that underpin safe and effective management 
of therapy. Surprisingly, “frailty” was not mentioned by the 
GPs as a consideration in decision-making, despite the 
increasing awareness of this geriatric syndrome;
24
 previous 
studies have reported the impact of frailty on the use of 
antithrombotic therapy.
25,26
 
 
Following from this it was surprising, however, to note the 
relative lack of specific consideration regarding the risk of 
bleeding associated with antithrombotic therapy. None of 
the GPs explicitly stated that the risk of bleeding was a key 
determinant in decision-making, and none mentioned 
bleeding risk assessment tools
27,28
 that may assist with this 
(unlike the reference to the CHADS2 criteria
19
 when 
assessing the risk of stroke). This contrasts with previous 
studies, which have shown that GPs have historically 
focused on the perceived risks of therapy, over and above 
the benefits of therapy.
8
 To an extent this demonstrates an 
evolution in the approach to decision-making in primary 
care, with more emphasis placed on identifying and 
addressing those factors that increase the risk of bleeding 
so that anticoagulation can be appropriately prescribed to 
prevent stroke.
29
 Indeed, recent practice guidelines 
emphasise that bleeding risk assessment tools should be 
used to identify factors that may increase the risk of 
bleeding so that they can be appropriately managed or 
“modified”.
30
 In this regard, it may be argued that bleeding 
risk is less a determinant in decision-making per se, and 
more a consideration in the management of therapy. 
Another explanation may be that the advent of the NOACs 
has directed attention to the practical aspects of treatment 
use, rather than the relative risks of bleeding, which are 
associated with all anticoagulant therapy.
31
 
 
In part, the transition of responsibility of care for AF 
patients to general practice is the result of increased access 
to services to support both GPs and patients in the 
management of therapy. In particular, the implementation 
of on-site services, such as practice nurses
32,33
 and point-of-
care testing (for monitoring coagulation parameters),
34
 has 
allowed GPs to more closely monitor their patients and 
streamline care. The fact that GPs have access to relevant 
services is positive, but more importantly, this study has 
shown no apparent differences in access between practice 
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settings across a range of geographical areas ranging from 
metropolitan to regional and rural settings, in contrast to 
concerns raised in previous studies.
35,36
 
 
Furthermore, there are other medication management 
services available now to support GPs and their patients. 
For example, medication management review services [such 
as Home Medicines Review (HMR) provided by accredited 
pharmacists],
37
 provide a platform for the comprehensive 
review of an individual’s pharmacotherapy and the 
generation of key recommendations to further optimise 
therapy.
13
 The latter service is important, given that it 
provides an avenue to assess and monitor a patient’s 
adherence to therapy,
38
 which is an issue commonly cited 
by the GPs as determining the initiation of therapy.
39,40
 The 
medication management review process also provides a 
framework for the follow-up and support of patients on 
anticoagulant therapy, particularly those transitioning from 
hospital back to primary care. An Australian study has 
previously demonstrated the benefits of a medication 
review service complemented by point-of-care testing (for 
coagulation parameters) in improving the quality of 
anticoagulation (i.e., time in therapeutic range), improving 
clinical outcomes, and improving patients’ adherence (in 
terms of persistence) with anticoagulant therapy.
41
 
 
In drawing conclusions from the findings of this study, it is 
important to acknowledge several limitations. First, the 
findings are based on self-report from a self-selected 
sample of GPs (who were willing to participate in the study) 
and it is possible that the responses received may not 
accurately reflect GPs’ actual management of patients; 
however, the sample is broadly representative of Australian 
general practice, comparable to that reported in the BEACH 
program.
16
 Second, the range of services accessible by GPs 
may not be actually used in practice for patient care. Third, 
the findings are based on the management of AF patients, 
where warfarin has been the mainstay of therapy; with the 
expanding access to the NOACs, the management 
approaches to AF patients may be further evolving. All in all, 
however, this study provides valuable insight into the 
contemporary management of AF in Australian general 
practice. In particular, it shows that it has moved away from 
emphasis on the “error of commission” to a focus on the 
“error of omission”, such that the benefits of therapy are 
now considered ahead of the risks. More attention needs to 
be paid, however, to supporting patients’ adherence to 
therapy. 
  
 
 
Conclusion 
Australian GPs are actively engaged in managing AF, and are 
well resourced in terms of services and resources. 
Importantly, there is a greater focus on the benefits of 
therapy during decision-making, rather than the risks. 
However, medication safety considerations affecting 
routine management of therapy remain key concerns, with 
patients’ cognitive or functional impairments, as well as 
adherence to therapy, serving as major determinants in 
decision-making. 
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Table 1: General characteristics of GPs and their practice sites 
Characteristic  
 
[number of GPs (% in subgroup)] 
Regional 
Urban 
n=12 (24.0%) 
Regional 
Rural 
n=11 (22.0%) 
Coastal 
Region 
n=18 (36.0%) 
City 
Metropolitan     
n=9 (18.0%) 
Total 
 n=50 (100.0%) 
GPs age (years), mean ± SD 51.00±8.53a 53.73±7.93 51.5±9.07 61.89±12.45 53.74±9.94 
Years of experience in practice 20.00±9.46 23.73±10.63 21.33±9.90 28.78±9.94 22.88±10.14 
Gender 
     
Male 10(83.3) 8(72.7) 11(61.1) 6(66.7) 35(70.0) 
Female 2(16.7) 3(27.3) 7(38.9) 3(33.3) 15(30.0) 
Type of practice 
     
Sole practice  2(16.7) 4(36.4) 2(11.1) 5(55.6) 13(26.0) 
Partnership 1(8.3) 0(0.0) 0(0.0) 1(11.1) 2(4.0) 
Small medical centre (≤3 GPs) 2(16.7) 2(18.2) 4(22.2) 0(0.0) 8(16.0) 
Medium medical centre (4–5 GPs) 4(33.3) 4(36.4) 6(33.3) 1(11.1) 15(30.0) 
Large medical centre (≥6 GPs) 3(25.0) 1(9.1) 6(33.3) 1(11.1) 11(22.0) 
Other practice type 0(0.0) 0(0.0) 0(0.0) 1(11.1) 1(2.0) 
Type of specialisation 
    
General/Family practice 12(100.0) 11(100.0) 18(100.0) 9(100.0) 50(100.0) 
Aged care/Geriatric medicine 0(0.0) 3(27.3) 3(16.7) 1(11.1) 7(14.0) 
Paediatric medicine 0(0.0) 4(36.4) 3(16.7) 0(0.0) 7(14.0) 
Women's Health 2(4.0) 4(36.4) 5(27.8) 0(0.0) 11(22.0) 
Heart/Vascular 0(0.0) 3(27.3) 2(11.1) 0(0.0) 5(10.0) 
Respiratory/Asthma 0(0.0) 3(27.3) 3(16.7) 0(0.0) 6(12.0) 
Diabetes/Endocrine 1(2.0) 2(18.2) 2(11.1) 0(0.0) 5(10.0) 
Other  1(2.0) 2(18.2) 2(11.1) 0(0.0) 5(10.0) 
Diagnostic and monitoring services* 
    
Pathology collection 9(75.0) 7(63.6) 13(72.2) 7(77.8) 36(72.0) 
Scans and imaging 0(0.0) 1(9.1) 3(16.7) 0(0.0) 4(8.0) 
Point-of-care testing 9(75.0) 9(81.8) 16(88.9) 4(44.4) 38(76.0) 
Urine testing 11(91.7) 11(100.0) 18(100.0) 7(77.8) 47(94.0) 
Respiratory tests 10(83.3) 10(90.9) 16(88.9) 4(44.4) 40(80.0) 
Cardiovascular tests 10(83.3) 9(81.8) 17(94.4) 7(77.8) 43(86.0) 
Other 1(8.3) 0(0.0) 2(11.1) 2(22.2) 5(10.0) 
Patient support services 
     
Home visits 11(91.7) 11(100.0) 14(77.8) 9(100.0) 45(90.0) 
After-hours visits 5(41.7) 10(90.9) 13(72.2) 6(66.7) 34(68.0) 
Point-of-care testing 11(91.7) 9(81.8) 15(83.3) 4(44.4) 39(78.0) 
On-site nurse 11(91.7) 10(90.9) 16(88.9) 8(88.9) 45(90.0) 
On-site allied health services 6(50.0) 7(63.6) 9(50.0) 2(22.2) 24(48.0) 
Medication management reviews 10(83.3) 9(81.8) 12(66.7) 4(44.4) 35(70.0) 
Disease state management 5(41.7) 5(45.5) 12(66.7) 4(44.4) 26(52.0) 
Other  0(0.0) 0(0.0) 2(11.1) 0(0.0) 2(4.0) 
Estimated proportion of patient-base that is elderly (≥65years)  
5–10% of patient base 0(0.0) 0(0.0) 2(11.1) 0(0.0) 2(4.0) 
10–25% of patient base 5(41.7) 5(45.5) 5(27.8) 1(11.1) 16(32.0) 
25–50% of patient base 5(41.7) 2(18.2) 3(16.7) 7(77.8) 17(34.0) 
50–75% of patient base 2(16.7) 4(36.4) 6(33.3) 1(11.1) 13(26.0) 
>75% of patient base 0(0.0) 0(0.0) 2(11.1) 0(0.0) 2(4.0) 
Estimated proportion of patient-base that has AF  
5–10% of patient base 0(0.0) 0(0.0) 1(5.6) 0(0.0) 1(2.0) 
10–25% of patient base 4(33.3) 6(54.5) 6(33.3) 5(55.6) 21(42.0) 
25–50% of patient base 6(50.0) 4(36.4) 7(38.9) 2(22.2) 19(38.0) 
50–75% of patient base 2(16.7) 0(0.0) 4(22.2) 1(11.1) 7(14.0) 
>75% of patient base 0(0.0) 1(9.1) 0(0.0) 1(11.1) 2(4.0) 
SD = standard deviation 
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Table 2: Management of patients with AF 
Management approach 
 
[number of GPs (% within sub-group)] 
Regional 
Urban 
n=12 
(24.0%) 
Regional 
Rural 
n=11 
(22.0%) 
Coastal 
Region 
n=18 
(36.0%) 
City 
Metropolitan 
n=9  
(18.0%) 
Total 
n=50 
(100.0) 
Individual assuming primary responsibility for management of patient with AF:    
Myself (as patient's GP) 11(91.7) 11(100.0) 18(100.0) 9(100.0) 49(98.0) 
Cardiologist 1(8.3) 0(0.0) 1(5.6) 0(0.0) 2(4.0) 
Other 0(0.0) 0(0.0) 1(5.6) 0(0.0) 1(2.0) 
Context for referral to specialist management of anti-arrhythmic therapy:   
Only as needed 6(50.0) 8(72.7) 8(44.4) 5(55.6) 27(54.0) 
For initial assessment only 5(41.7) 4(36.4) 7(38.9) 0(0.0) 16(32.0) 
For initial + regular follow-up (complete) 0(0.0) 0(0.0) 0(0.0) 1(11.1) 1(2.0) 
For initial + periodic follow-up only 1(8.3) 0(0.0) 3(16.7) 3(33.3) 7(14.0) 
Context for referral to specialist management of anti-thrombotic therapy:  
Only as needed 7(58.3) 9(81.8) 14(77.8) 4(44.4) 34(68.0) 
For initial assessment only 4(33.3) 2(18.2) 2(11.1) 2(22.2) 10(20.0) 
For initial + regular follow-up (complete) 0(0.0) 0(0.0) 1(5.6) 1(11.1) 2(4.0) 
For initial + periodic follow-up only 1(8.3) 0(0.0) 1(5.6) 2(22.2) 4(8.0) 
Approach to monitoring & managing anticoagulant therapy:   
Local pathology clinic with GP follow-up 9(75.0) 7(63.6) 6(33.3) 7(87.5) 29(59.2) 
GP-based on-site monitoring and review 8(66.7) 7(63.6) 15(83.3) 3(37.5) 33(67.3) 
* Some GPs used both local pathology clinics and on-site monitoring. 
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Table 3: Determinants for decision making for the initiation of antithrombotic therapy by GPs 
Determinants for 
decision-making 
[number of GPs (% 
within subgroup)]  
FIRST 
determinan
t n=51 GPs 
(25.1%) 
SECOND 
determinan
t n=55 GPs 
(27.1%) 
THIRD 
determinant 
n=52 GPs 
(25.6%) 
Fourth 
determinant 
n=30 GPs 
(14.8%) 
FIFTH 
determinant 
n=15 GPs 
(7.4%) 
Total 
determinant 
N=203 
(100.0) 
Theme: Perceived benefit of therapy 
CHADS2 score 15(29.4) - 1(1.9) 1(3.3) - 17(8.4%) 
Stroke risk 9(17.6) 7(12.7) 2(3.8) 1(3.3) - 19(9.4) 
Confirmed diagnosis of 
AF 
7(13.7) 3(5.5) 5(9.6) - - 15(7.4) 
Advice of specialist - - 1(1.9) - - 1(0.5) 
Treatment strategy 5(9.8) 1(1.8) - - - 6(3.0) 
Diabetes mellitus - - 1(1.9) 1(3.3) - 2(1.0) 
Other cardiovascular 
issue  
1(2.0) 2(3.6) 1(1.9) 4(13.3) 1(6.7) 9(4.4) 
Theme: Perceived risks associated with therapy  
Contraindication 3(5.9) 2(3.6) 2(3.8) - - 7(3.4) 
Suitability for therapy* - 4(7.3) - - 1(6.7) 5(2.5) 
Safety (adverse effects) 1(2.0) 6(10.9) 2(3.8) 2(6.7) 2(13.3) 13(6.4) 
Theme: Medication safety considerations impacting on the day-to-day management of therapy  
Adherence/compliance 2(3.9) 5(9.1) 10(19.2) - - 17(8.4) 
Comorbidities 1(2.0) 5(9.1) 3(5.8) 2(6.7) 1(6.7) 12(5.9) 
Allergies - - 1(1.9) - 3(20.0) 4(2.0) 
Benefit of therapy - 2(3.6) - - 1(6.7) 3(1.5) 
Renal/liver/GI change - - - - 1(6.7) 1(0.5) 
Cognitive/mental 
status 
- 4(7.3) 10(19.2) 1(3.3) - 15(7.4) 
Fall risk/mobility 1(2.0) 4(7.3) 4(7.7) 2(6.7) - 11(5.4) 
Cost - - - 2(6.7) - 2(1.0) 
History (medical) - 3(5.5) 2(3.8) 4(13.3) - 9(4.4) 
Patient age 6(11.8) 2(3.6) 3(5.8) 2(6.7) 2(13.3) 15(7.4) 
Life quality - 1(1.8) - - 1(6.7) 2(1.0) 
Drug interactions - 1(1.8) 2(3.8) 3(10.0) - 6(3.0) 
Monitoring and 
support 
- - 1(1.9) 4(13.3) 2(13.3) 7(3.4) 
Patient preference - 3(5.5) - 1(3.3) - 4(2.0) 
Social factors - - 1(1.9) - - 1(0.5) 
* ≤5 GPs provided more than one entry to indicate more than one “equal” determinant. 
**Therapy refers to anticoagulation.  GPs were able to cite up to a maximum of five determinants of therapy, ranking 
them in order of priority as considerations in decision-making. 
 
